BIM
STML

Bogle Investment Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Bogle Investment Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-94,945
Closed -$1.01M – 417
2016
Q4 		$1.01M Buy
+94,945
New +$1.15M 0.07% 251

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Bogle Investment Management's STML Position: Q1 2017 in Review

Bogle Investment Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2017, closing a stake of 94,945 shares — an estimated $1.01M sold.

Bogle Investment Management first reported a position in STML in Q4 2016 and held it in 1 quarter. The position peaked at $1.01M in Q4 2016. 75 funds tracked by Wall St. Rank hold STML as of Q1 2017.

  • Bogle Investment Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Bogle Investment Management sold 94,945 Stemline Therapeutics, Inc. shares in Q1 2017, an estimated $1.01M.
  • Bogle Investment Management first reported a position in Stemline Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
  • Bogle Investment Management's Stemline Therapeutics, Inc. position peaked at $1.01M in Q4 2016.
  • 75 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2017.

Based on Bogle Investment Management's 13F filing for Q1 2017, filed 12 May 2017.